Grape Seed Extract for Blood Pressure: A Realistic Result
Informational summary of published research — not medical advice. Never reduce or stop prescribed blood pressure medication based on this page. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Grape seed extract can modestly lower blood pressure in some people — the honest answer is a few millimeters of mercury on average, bigger if you're younger, obese, or have metabolic syndrome, and possibly nothing at all if you don't. Three meta-analyses agree the effect is real; one well-designed RCT found it wasn't statistically significant in its own sample. Every number below is a risk-factor marker, not a proven cardiovascular outcome, and GSE should never replace prescribed blood pressure medication.
Feringa 2011: the conservative foundation
Feringa 2011 pooled 9 RCTs (N=390) to look at grape seed extract's effect on multiple cardiovascular risk markers. PRIMARY ENDPOINTS were SBP, DBP, heart rate, lipids, and CRP. The result: SBP was significantly lowered by a modest 1.54 mmHg (95% CI −2.85 to −0.22) and heart rate fell 1.42 bpm — but DBP, every lipid parameter, and CRP showed no significant change. Heterogeneity across the pooled trials was low (I²<39%), meaning the trials largely agreed with each other, which makes this small effect size more, not less, credible as a floor estimate. The authors' own conclusion calls for "larger randomized, double-blinded trials evaluating different dosages... and longer follow-up" — a genuinely cautious meta-analysis, and the smallest effect size of the three covered here.
Zhang 2016: the bigger effect, and who it's biggest for
Zhang 2016 pooled a larger set — 16 trials, N=810 — with SBP/DBP change as the PRIMARY ENDPOINT, and found a larger overall effect: SBP down 6.08 mmHg (95% CI −10.74 to −1.42), DBP down 2.80 mmHg (95% CI −4.42 to −1.19). The subgroup analysis is the load-bearing finding for this page: the effect was significantly larger in people under 50 (SBP −6.05, DBP −3.12), in people with obesity (SBP −4.47), and largest of all in people with metabolic syndrome (SBP −8.49, p<0.001). Meta-regression across all 16 trials found that older age, lower BMI, and lower baseline blood pressure were each independently associated with a smaller effect. The authors disclose no conflicts of interest, but themselves flag small individual trial sizes and call for "a large-scale, long-term, multiple-dose RCT, especially among hypertensive patients."
Foshati 2022: the most comprehensive, and the disagreement it reveals
Foshati 2022 is the most recent and largest of the three (19 trials), with PRIMARY ENDPOINTS of flow-mediated dilation (FMD), SBP, DBP, and heart rate. Here the pattern flips: DBP was significantly reduced (−2.20 mmHg, I²=88.8%) and heart rate fell (−1.25 bpm), but SBP showed no significant change (−3.55 mmHg, 95% CI −7.59 to 0.49, I²=97.4% — very high heterogeneity and a wide confidence interval crossing zero), and FMD (a measure of blood vessel function) also showed no significant change. Significant non-linear dose- and duration-response relationships were found for DBP specifically. This is the evidence-quality tension worth naming directly: Feringa and Zhang both found a significant SBP effect; Foshati, using more trials and more recent data, did not — while finding a DBP effect Feringa didn't. Three independent meta-analyses, three different combinations of pooled trials, and disagreement on which blood pressure number actually moves.
Ras 2013: the null RCT that keeps the picture honest
Pooled meta-analyses can make an effect look more settled than any individual well-designed trial supports. Ras 2013 is the direct counterweight: a double-blind, placebo-controlled RCT (n=70) in real pre- and stage-1-hypertensive adults (untreated, SBP 120–159 mmHg), using 24-hour ambulatory blood pressure monitoring — a more objective measure than a single office reading — at 300mg/day for 8 weeks. PRIMARY ENDPOINT was ambulatory blood pressure, and the result was explicit: "GSE treatment did not significantly lower ABP," with an effect of −3.0 mmHg SBP (95% CI −6.5 to 0.5, crossing zero) and −1.4 mmHg DBP (CI also crossing zero). Vasoactive markers (endothelin-1, nitric oxide metabolites, plasma renin activity) and platelet aggregation were also unaffected. The trial was run by Unilever R&D — industry-funded, but a company's own trial failing to support its product's mechanism is informative, not something to discount for conflict of interest.
The honest framing Three independent meta-analyses converge on a real, small, replicated blood-pressure-lowering effect from grape seed extract — genuinely one of the better-evidenced findings in this supplement category. But the effect is a few mmHg on average, meaningfully bigger if you're younger, obese, or have metabolic syndrome, and one well-designed RCT found no significant effect in its own sample. This is a modest risk-marker effect, not a blood-pressure-drug replacement — and it should never be a reason to reduce or stop prescribed antihypertensive medication.
As an Amazon Associate we earn from qualifying purchases. Ranked by disclosed standardization, never commissions.
Frequently asked questions
How much does grape seed extract lower blood pressure?
A few mmHg on average across meta-analyses (SBP -1.5 to -6.1, DBP up to -2.8), bigger in younger/obese/metabolic-syndrome subgroups. One well-designed RCT found no significant effect.
Who's most likely to benefit?
Zhang 2016 found significantly bigger effects in people under 50, with obesity, or with metabolic syndrome — smaller or absent in leaner, older people with lower baseline blood pressure.
Can it replace blood pressure medication?
No. Every trial measures a surrogate marker over weeks to months, not a hard outcome like stroke or heart attack. Never reduce or stop prescribed medication.
Related
- Grape Seed Extract: what it is & who it's for
- Dosage Guide — the trial dose range, honestly
- Best Grape Seed Extract Supplement — ranked by standardization
- Does Grape Seed Extract Actually Lower Blood Pressure? — the full meta-analysis reckoning
- Garlic for Blood Pressure — another cardiovascular botanical with real but modest evidence
- Berberine for Blood Sugar — the metabolic-syndrome-responder pattern, in a different botanical
Sources
- Feringa HH, Laskey DA, Dickson JE, Coleman CI. "The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials." Journal of the American Dietetic Association. 2011. PMID: 21802563
- Zhang H, Liu S, Li L, et al. "The impact of grape seed extract treatment on blood pressure changes: A meta-analysis of 16 randomized controlled trials." Medicine (Baltimore). 2016. PMID: 27537554
- Foshati S, Nouripour F, Sadeghi E, et al. "The effect of grape (Vitis vinifera) seed extract supplementation on flow-mediated dilation, blood pressure, and heart rate: A systematic review and meta-analysis of controlled trials with duration- and dose-response analysis." Pharmacological Research. 2022. PMID: 34798267
- Ras RT, Zock PL, Zebregs YE, et al. "Effect of polyphenol-rich grape seed extract on ambulatory blood pressure in subjects with pre- and stage I hypertension." British Journal of Nutrition. 2013. PMID: 23702253
- Bijak M, Sut A, Kosiorek A, et al. "Dual Anticoagulant/Antiplatelet Activity of Polyphenolic Grape Seeds Extract." Nutrients. 2019. PMID: 30621248 (in vitro; mechanistic basis for the safety caution.)